Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

By afschroeder • August 20, 2025

Cheon J, Ryoo BY, Chon HJ, Kim HD, Ryu MH, Kim KP, Kang B, Finn RS, Chan SL, Yoo C. Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab. Liver Cancer. 2025 Jan 21;14(4):446-455. doi: 10.1159/000543666. PMID: 40831890; PMCID: PMC12360742.

Tags: Atezolizumab, Bevacizumab, Hematology/Oncology, Hepatocellular carcinoma, Publications, regorafenib, Tyrosine kinase inhibitor

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis[...]

Pregnancy and breast cancer in young women: current updates and future directions

Zhang S, Guclu SB, Lipsyc-Sharf M, Kapoor NS. Pregnancy and breast cancer in young women: current updates and future directions. Ther Adv Med Oncol. 2025[...]

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

Falchi L, Sureda A, Leppä S, Vermaat JS, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton K,[...]